RT Journal Article
SR Electronic
T1 Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6501
OP 6506
DO 10.21873/anticanres.13014
VO 38
IS 11
A1 TOSHIKI MASUISHI
A1 HIROYA TANIGUCHI
A1 TETSUYA ETO
A1 AZUSA KOMORI
A1 SEIICHIRO MITANI
A1 HIROKO HASEGAWA
A1 YUKIYA NARITA
A1 MAKOTO ISHIHARA
A1 TSUTOMU TANAKA
A1 SHIGENORI KADOWAKI
A1 TAKASHI URA
A1 MASASHI ANDO
A1 MASAHIRO TAJIKA
A1 MOTOO NOMURA
A1 YOZO SATO
A1 HIDEYUKI MISHIMA
A1 KEI MURO
YR 2018
UL http://ar.iiarjournals.org/content/38/11/6501.abstract
AB Background/Aim: Anti-EGFR antibodies or bevacizumab comprise first-line treatment for patients with RAS wild-type colorectal liver metastases (CLM). Which marker better predicts efficacy, early tumor shrinkage or morphologic response, still remains unclear. Patients and Methods: We retrospectively evaluated 155 patients with KRAS exon 2 wild-type CLM treated with bevacizumab (BEV group) or anti-EGFR antibodies (EGFR group). Three radiologists independently assessed early tumor shrinkage (ETS) and early optimal morphologic response (EOMR) from baseline and first follow-up CT scan. Results: Patients with ETS had longer progression-free survival (PFS) than those without ETS [hazard ratio (HR)=0.69] and ETS tended to be observed in the EGFR group, while patients with EOMR had longer PFS than those without EOMR (HR=0.64) and EOMR tended to be observed in the BEV group. Conclusion: Among patients with KRAS exon 2 wild-type CLM, EOMR and ETS may predict better PFS, especially in patients treated with bevacizumab and anti-EGFR antibodies, respectively.